Skip to main content
OpenTrials
Completed

NCT Number: NCT07528911

Elements of Adaptive Immunity in Epithelial Ovarian Cancer

The study seeks to evaluate the presence and correlation with clinical outcome of several components of adaptive immunity (TILs, TLS, plasma cells and PD-L1 expression) in tumor specimens of patients with EOC treated with carboplatin/paclitaxel chemotherapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Epithelial High Grade Serous Ovarian Cancer Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Tertiary Lymphoid Structures

Sex eligibility

Female

Study type

Observational

Primary location

Hellenic Cooperative Oncology Group

Athens, Greece

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with advanced high grade serous ovarian cancer treated with carboplatin/paclitaxel chemotherapy

Exclusion criteria

  • Any other histology than high grade ovarian cancer
  • Patients with stages I-II (based on FIGO staging)

Treatment and study plan

Assessment of elements of adaptive immunity in tumor biopsies

Other

Tertiary lymphoid structures, Plasma cells, p53 and CD8+ T cells will be evaluated at tumor biopsies of patients with advanced ovarian cancer treated with chemotherapy.

Primary outcomes

  1. Assessment of: Tertiary Lymphoid Structures (presence, absence) in tumor biopsies

    Time frame: through study completion, an average of 3 years

Secondary outcomes

  1. Plasma cells (4-tiered score)

    Time frame: 3- years time frame (upon study completion)

  2. PD-L1 score (TPS score) in tumor biopsies

    Time frame: upon study completion (3 years)

  3. CD8 cells (low : <5 cells/HPF vs high (> 5 cells/HPF) expression) in tumor biopsies

    Time frame: upron study completion (3 years)

  4. p53 (presence, absence) in tumor biopsies (immunohistochemistry)

    Time frame: upon study compeltion (3 years)

Sponsors and collaborators

Lead sponsor

Hellenic Cooperative Oncology Group

Other

Collaborators

  • Attikon Hospital

Registry information

Official study title

Prognostic Significance of Adaptive Immunity Cell Infiltrates in the Microenvironment of High-grade Serous Ovarian Cancer

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Apr 14, 2026
Registry last updated
Jul 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.